162
Participants
Start Date
June 9, 2017
Primary Completion Date
July 5, 2022
Study Completion Date
August 24, 2022
NKTR-214
NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
Pembrolizumab
Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.
NKTR-214
NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion.
NKTR-214
NKTR-214: The dose will be 0.010 mg/kg intravenous (IV) infusion.
Cisplatin
Cisplatin will be dosed per the pharmacy manual
Carboplatin
Carboplatin will be dosed per the pharmacy manual
Nab paclitaxel
Nab-paclitaxel will be dosed per local practice and label
Paclitaxel
Paclitaxel will be dosed per local practice and label
Pemetrexed
Pemetrexed will be dosed per the pharmacy manual
Atezolizumab
Atezolizumab will be dosed per current label indication
Centre Hospitalier de Saint-Quentin, Saint-Quentin
Epworth HealthCare, Richmond
New York University Langone Medical Center, New York
Columbia University Medical Center, New York
Vivantes Klinikum Spandau, Berlin
Fox Chase Cancer Center, Philadelphia
Inova Melanoma and Skin Cancer Center, Fairfax
LungenClinic Grosshansdorf, Großhansdorf
Universitätsklinikum Schleswig-Holstein, Lübeck
Blue Ridge Cancer Care, Roanoke
Duke Clinical Research Institute, Durham
Hospital Clínico San Carlos, Madrid
Hospital Universitario Fundacion Jimenez Diaz, Madrid
HM Universitario Sanchinarro, Madrid
Augusta University - Augusta University Medical Center, Augusta
Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium), Nashville
West Cancer Center, Germantown
Hospital Universitari i Politècnic La Fe, Valencia
Henry Ford Hospital, Detroit
Froedtert & the Medical College of Wisconsin Froedtert Hospital, Milwaukee
Park Nicollet - Frauenshuh Cancer Center, Saint Louis Park
Lungenklinik Hemer, Hemer
St. Vincent Frontier Cancer Center, Billings
Washington University School of Medicine in St. Louis, St Louis
University of Nebraska Medical Center, Omaha
Robert-Bosch-Krankenhaus, Stuttgart
Ochsner Medical Center, New Orleans
Highlands Oncology Group, PA - North Hills, Fayetteville
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Anschutz Medical Campus, Aurora
Asklepios Fachkliniken München-Gauting, Gauting
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley, Las Vegas
California Pacific Medical Center, San Francisco
Northwest Medical Specialties, Tacoma
Rutgers Cancer Institute of New Jersey, New Brunswick
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitario Vall d'Hebron, Barcelona
Lead Sponsor
Nektar Therapeutics
INDUSTRY